Moving targets in drug discovery

被引:19
|
作者
Zdrazil, Barbara [1 ]
Richter, Lars [1 ]
Brown, Nathan [2 ]
Guha, Rajarshi [3 ]
机构
[1] Univ Vienna, Dept Pharmaceut Chem, Div Drug Design & Med Chem, Althanstr 14, A-1090 Vienna, Austria
[2] BenevolentAI, 4-8 Maple St, London W1T 5HD, England
[3] Vertex Pharmaceut, 50 Northern Ave, Boston, MA 02210 USA
关键词
INHIBITOR; POLYPHARMACOLOGY; RECEPTOR; OPPORTUNITIES; INFORMATION; CUDC-101; ALPHA;
D O I
10.1038/s41598-020-77033-x
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Drug Discovery is a lengthy and costly process and has faced a period of declining productivity within the last two decades resulting in increasing importance of integrative data-driven approaches. In this paper, data mining and integration is leveraged to inspect target innovation trends in drug discovery. The study highlights protein families and classes that have received more attention and those that have just emerged in the scientific literature, thus highlighting novel opportunities for drug intervention. In order to delineate the evolution of target-driven research interest from a biological perspective, trends in biological process annotations from Gene Ontology and disease annotations from DisGeNET are captured. The analysis reveals an increasing interest in targets related to immune system processes, and a recurrent trend for targets involved in circulatory system processes. At the level of diseases, targets associated with cancer-related pathologies, intellectual disability, and schizophrenia are increasingly investigated in recent years. The methodology enables researchers to capture trends in research attention in target space at an early stage during the drug discovery process. Workflows, scripts, and data used in this study are publicly available from https://github.com/BZdrazil/Moving_Targets. An interactive web application allows the customized exploration of target, biological process, and disease trends (available at https://rguha.shinyapps.io/MovingTargets/).
引用
收藏
页数:15
相关论文
共 50 条
  • [21] HCN Channels as Targets for Drug Discovery
    Maher, Michael P.
    Wu, Nyan-Tsz
    Guo, Hong-Qing
    Dubin, Adrienne E.
    Chaplan, Sandra R.
    Wickenden, Alan D.
    COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, 2009, 12 (01) : 64 - 72
  • [22] Tuberculosis drug discovery and emerging targets
    Mdluli, Khisimuzi
    Kaneko, Takushi
    Upton, Anna
    ANTIMICROBIAL THERAPEUTICS REVIEWS: INFECTIOUS DISEASES OF CURRENT AND EMERGING CONCERN, 2014, 1323 : 56 - 75
  • [23] Kinase targets in CNS drug discovery
    Gunosewoyo, Hendra
    Yu, Lifang
    Munoz, Lenka
    Kassiou, Michael
    FUTURE MEDICINAL CHEMISTRY, 2017, 9 (03) : 303 - 314
  • [24] Molecular targets for flavivirus drug discovery
    Sampath, Aruna
    Padmanabhan, R.
    ANTIVIRAL RESEARCH, 2009, 81 (01) : 6 - 15
  • [25] Novel Targets for Hypertension Drug Discovery
    Bhatt, Lokesh Kumar
    Selokar, Ishant
    Raut, Dezaree
    Hussain, Tahir
    CURRENT HYPERTENSION REPORTS, 2021, 23 (04)
  • [26] Novel Targets for Hypertension Drug Discovery
    Lokesh Kumar Bhatt
    Ishant Selokar
    Dezaree Raut
    Tahir Hussain
    Current Hypertension Reports, 2021, 23
  • [27] UBIQUITIN LIGASES AS TARGETS FOR DRUG DISCOVERY
    Fang, Shengyun
    Ballar, Petek
    IUBMB LIFE, 2009, 61 (03) : 310 - 310
  • [28] Novel targets for tuberculosis drug discovery
    Mdluli, Khisimuzi
    Spigelman, Melvin
    CURRENT OPINION IN PHARMACOLOGY, 2006, 6 (05) : 459 - 467
  • [29] Genomics and the discovery of new drug targets
    Jones, DA
    Fitzpatrick, FA
    CURRENT OPINION IN CHEMICAL BIOLOGY, 1999, 3 (01) : 71 - 76
  • [30] Moving smaller in drug discovery and delivery
    LaVan, DA
    Lynn, DM
    Langer, R
    NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (01) : 77 - 84